PANEL DISCUSSION: BIOMARKERS AND OUTCOME MEASURES IN PD CLINICAL TRIALS

ISCTM Symposium
February 22, 2018
BIOMARKERS AND OUTCOME MEASURES IN PD CLINICAL TRIALS

Diane Stephenson, PhD
Executive Director, Critical Path for Parkinson’s
Acting Director, Huntington’s Disease Regulatory Science Consortium

Luca Pani, MD
Professor of Clinical Psychiatry
University of Miami

Christopher Leptak, MD, PhD
OND Biomarker Qualification Lead
CDER/FDA

David Stamler, MD
Chief Medical Officer
Prana Biosciences
QUESTIONS FOR DISCUSSION

» How would you utilize and integrate existing biomarkers into Parkinson’s clinical trials?

» What are the challenges in testing interventions in genetically defined populations of Parkinson’s patients?

» What are the scientific and regulatory considerations to testing an intervention in a ‘prodromal’ PD population?